Phase II trial of the oral platinum comples JM216 in non-small-cell lung cancer: An EORTC early clincal studies group investigation

Annals of Oncology

Volumn 8, Issue 6, 1997, Pages 604-606

  Judson, I ^a,i   Cerny, T ^b   Epelbaum, R ^c   Dunlop, D ^d   Smyth, J ^e   Schaefer, B ^f   Roelvink, M ^g   Kaplan, S ^g   Hanauske, A ^h  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c RAMBAM MEDICAL CENTER   (Israel)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f New Drug Development Office   (Netherlands)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

JM216; Lung cancer; Non small cell; Oral chemotherapy, platinum

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; SATRAPLATIN;

AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 0031159653     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008245709924     Document Type: Article

References (8)

1. Cancer Statistics. 1992. ÇA 1992; 42: 19-38.
2. Kris M, Cohen E. Gralla R. An analysis of 134 phase il trials in non-small ceil lung cancer IV. Toronto: World Conference on Lung Cancer 1985:39.
3. Giandomenico CM. Abrams MI. Murrer BA et al. Synthesis and reactions of a new class of orally active Pl(JV) antitumour complexes. In Howell SB (ed): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. New York: Plenum Press 1991:93-100.
4. Keliand LR. Abel G. McKeage MJ. Precliaical antitumour evaluation of bis-aceuuo-ammine-dichloro-cyclohexyiarniue platinum (IV): An orally active platinum drug. Cancer Res 1993: 53: 2581-6.
5. McKeage MJ. Morgan SE. Boxall FE el al. Preciinical toxicology and tissue distribution of r.ovei oral antitumour platinum complexes: Ammine.amine platinum (IV) dicarboxylates. Cancer Chemother Pharmacol 1994: 33: 497-503.
6. McKeage MJ. Morgan SE. Boxall FE et al. Lack of ncphrotoxicih of oral ammine-amine platinum (IV; dicarboxylate complexes in rodents. Br J Cancer 1993: 67: 996-1000.
7. Judson I. McKeage M. Raynaud F et al. A phase I trial of the oral platinum amicancer drug JM216 complex [Af-Wj(acetato)-Bammine-cu-dichloro-E-cyclohexylamin platinum (IV)]. Ann Oncol 1994; 5 (Suppl 5): 126.
8. Bann PA Jr. Review of iherapeutic trials of carbonlatin in lung cancer. Semin Oncol 1989; 16 (Suppl 5): 27-33.